An ISO9001 Certified Supplier of Pharmaceutical Ingredients and Specialty Chemicals

CRENESSITY®

Drug Information Related Patent

Hold Company

NEUROCRINE

Learn More

Dosage and Administration

SOLUTION ORAL; CAPSULE ORAL

Specification

50MG/ML (SOLUTION); 25MG/50/100MG(CAPSULE)

Indication

Crenessity® is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).

Use

Instructions for Use

API

CRINECERFONT

API Structure

We Supply

CRINECERFONT

Drug Patent

Patent No	Expiration Date
10905690	2035/1/21
11311544	2035/1/21
11730739	2035/1/21
12128033	2041/6/9

API Patent

Patent No	Expiration Date
10905690	2035/1/21
11311544	2035/1/21
11730739	2035/1/21
12128033	2041/6/9

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION